Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Advantagene Inc.
DescriptionCombination of vector AdV-tk (adenovirus thymidine kinase) and valacyclovir
Molecular Target
Mechanism of ActionGene therapy; Oncolytic virus
Therapeutic ModalityGene therapy: Viral vector: Adenovirus
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsPrevent prostate cancer recurrence; Treat intermediate to high risk localized prostate cancer; Treat prostate cancer
Regulatory Designation U.S. - Special Protocol Assessment (Prevent prostate cancer recurrence)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today